Business

Canadian Business Journal Produces Psilocybin

Vancouver, British Columbia, March 12, 2022 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: How nice), (OTC: CLABF),(Frankfurt: LD6WKN: A3CSSU) (“society” Also “Core One“) Is its wholly owned subsidiary Vocan Biotechnologies Inc. (“”Vokan”) Launches a move to expand the production of its own biosynthetic sirocibin API (active ingredient of pharmaceuticals) for use by licensed physicians for availability by pharmaceutical companies involved in the development of psychedelic drugs. Patient treatment delivered to a dispensing pharmacy for distribution to a licensed physician.

The unique production system for biosynthetic psilocybin developed by Vocan scientists (company press release dated January 21, 2022) is a system that produces the stereochemically correct psilocybin API, which is accurate and appropriate. It can be calibrated accurately while ensuring the dose. High level of purity.

We are currently in the process of expanding our production capacity through Vocan’s scientific R & D department to enable the deployment of our unique psilocybin API to GMP-compliant production facilities where we can further distribute our products to pharmaceutical companies. It provides a cost-effective, reliable and chemically stable source of psilocybin for organizations and facilities, research efforts.

Vocan supplies API-grade psilocybin to a licensed contract manufacturing organization (CDMO), encapsulates the company’s raw biosynthetic psilocybin, and is a customized concentration for deployment to doctors who have applied for approval and obtained it. We aim to expand our production capacity so that we can dispense psilocybin.On behalf of patients for access to psilocybin under Health Canada’s Special Access Program1..

“”Core One Labs has taken a new step towards bringing this cost-effective biosynthetic psilocybin to market first. We have established ourselves as a leader in psychedelic space through innovative and game-changing advances in psychedelic space. As we take the necessary steps to advance our products, we aim to build a pipeline of potential partners who desire to use high quality, high purity psilocybin for treatment and research.“” Said Joel Shacker, CEO of Core One.

About Core One Labs Inc.
Core One is a biotechnology research and technology life sciences company focused on bringing psychedelic drugs to market through new delivery systems and psychedelic-assisted psychotherapy. Through its wholly owned subsidiary Vocan, Core One has developed and filed a patent protection, a unique process for producing psilocybin using artificial bacteria. Core One has also developed a patent-pending thin-film oral strip. It dissolves as soon as it is placed in the mouth, sending the correct amount of organic molecules into the bloodstream and maintaining excellent bioavailability. We plan to further develop this technology and apply it to the delivery of psychedelic compounds such as psilocybin. Core One is also interested in clinics that maintain a combined database of over 275,000 patients. Through these clinics and the integration of intellectual property related to psychedelic and new drug therapies, we will obtain approval for regulatory research on advances in psychedelic-derived therapies for psychiatric disorders.

Core One Labs Inc.

Joel Shacker
Chief executive officer

Contact us for more information:
info@core1labs.com
1-866-347-5058

Disclaimer of caution:
The Canadian Stock Exchange has not considered the validity or accuracy of the content of this news release and is not responsible for it.

The information contained in this news release contains forward-looking statements based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. These do not guarantee future performance. We are inherently uncertain about all forward-looking statements, and actual performance may be affected by a number of key factors, many of which are beyond our control. Please note. Such factors include, among other things, the risks and uncertainties associated with our limited business history and the need to comply with strict regulations. Therefore, actual and future events, situations and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. We undertake no obligation to publicly update or revise any forward-looking information, except as required by applicable securities law.

In addition, psilocybin is now Controlled Drugs and Substances Act (Canada) And owning the substance underneath is a criminal offense Controlled Drugs and Substances Act (Canada) No prescription or permission. Health Canada does not approve psilocybin as an indication drug. Core One is not directly or indirectly involved in the illegal sale, manufacture or distribution of psychedelic substances in the jurisdiction in which it operates. Core One believes that psychedelic drugs can be used to treat certain medical conditions, but does not support the legalization of psychedelic drugs for recreational purposes. Core One does not handle psychedelic substances except within the setting of laboratory and clinical trials conducted within the framework of approved regulations.


1 Restricted drugs accessed through SAP (such as psilocybin) can be supplied directly by manufacturers to healthcare professionals, pharmacies, regional pharmacies, radiopharmaceuticals and blood banks.look https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access/drugs.html


CBJ News Maker

Canadian Business Journal Produces Psilocybin

Source link Canadian Business Journal Produces Psilocybin

Related Articles

Back to top button